Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: From bench top to bedside

Laryngoscope

Volumn 115, Issue 3, 2005, Pages 391-404

  O'Malley Jr , Bert W ^a   Li, Daqing ^a   McQuone, Shelly J ^a   Ralston, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Gene therapy; IL 2; Immunotherapy; Lipid formulations

Indexed keywords

CATION; CISPLATIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 GENE; LIPID; METHOTREXATE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTERY INJURY; ARTICLE; BLEEDING; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DYSPHAGIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE EDEMA; FEVER; GENE CASSETTE; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CANCER; HEADACHE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNOSTIMULATION; INJECTION PAIN; MOUSE; NAUSEA; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; METHOTREXATE; MICE; MICE, INBRED C3H; PALLIATIVE CARE; PLASMIDS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSGENES;

EID: 14744278451     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200503000-00002     Document Type: Article

References (36)

1. Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995;92:8522-8526.
2. Chen SH, Li Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon cancer in vivo. Proc Natl Acad Sci USA 1995;92:2577-2581.
3. Parker SE, Khatibi S, Margalith M, et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996;3:175-185.
4. Li D, Jiang W, Bishop JS, Ralston R, O'Malley BW Jr. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res 1999;5: 1551-1556.
5. O'Malley BW, Cope KA, Chen SH, et al. Combination gene therapy for oral cancer in a murine model. Cancer Res 1996;56:1737-1741.
6. O'Malley BW Jr, Li D, Buckner A, et al. Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope 1999;109:389-395.
7. Figlin RA, Parker SE, Horton HM. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma. Curr Opin Mol Ther 1999;1:271-278.
8. Hoffman DM, Figlin RA. Intratumoral interleukin-2 for renal cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000;18: 152-156.
9. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Huntingt) 2002;16(11 Suppl 13):4-10.
10. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10: 2253-2264.
11. Harlin H, Artz AS, Mahowald M, et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant 2004;33:491-497.
12. Yamamoto S, Yamamoto T, Shimada S, et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992;36:983-997.
13. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol 1996;167:72-78.
14. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-854.
15. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745. Erratum in Nature 2001;409:646.
16. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996;157: 1840-1845.
17. Yamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Lipofection of synthetic oligodeoxribonucleotide having a plain-dromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol 1994;38:831-836.
18. Klinman DM, Yi AK, Beucage SL, et al. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-gamma. Proc Natl Acad Sci U S A 1996;93:2879-2883.
19. Iho S, Yamamoto T, Takahashi T, Yamamoto S. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T-cells to induce IFN-gamma production in vitro. J Immunol 1999;163:3642-3652.
20. Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34: 251-262.
21. Freimark BD, Blezinger HP, Florack VJ, et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid:cationic lipid complexes. J Immunol 1998;160:4580-4586.
22. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5: 508-515.
23. Rosset MB, Ballerini C, Gregoire S, et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 2004; 172:5168-5174.
24. Conant SB, Swanborg RH. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J Immunol 2004;172:5322-5328.
25. Oldenhove G, de Heusch M, Urbain-Vansanten G, et al. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 2003;198:259-266.
26. Alila H, Coleman M, Nitta H, et al. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum Gene Ther 1997;8:1785-1795.
27. MacGregor GR, Caskey CT. Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res 1989;17:2365.
28. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-24.
29. Rolland A. From genes to gene medicines: recent advances in non-viral gene delivery. Crit Rev Ther Drug Carrier Syst 1998;15:143-198.
30. Tokunaga T, Yano O, Kuramoto E, et al. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol 1992;36:55-66.
31. Yamamoto S, Yamamoto T, Kataoka T, et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992;148:4072-4076.
32. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635-3639.
33. Scheule RK, St George JA, Bagley RG, et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Human Gene Ther 1997; 8:689-707.
34. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251.
35. Musiani P, Allione A, Modica A, et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 1996;74: 146-157.
36. van Ginkel FW, McGhee JR, Liu C, et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Immunol 1997;159:685-693.